05:55 PM EST, 02/13/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

EXAS delivered strong Q4 2025 results with total revenue of $878M (+23% Y/Y), driven by Screening revenue of $695M (+26% Y/Y) from strong Cologuard franchise performance and Precision Oncology revenue of $183M (+14% Y/Y). Gross margin improved 100 bps to 70% while adjusted EBITDA declined to $63M from $75M, primarily due to a $75M R&D expense related to the Freenome collaboration. The strong operational momentum demonstrates the value of EXAS's diversified cancer screening and diagnostics platform as the company approaches the closing of its acquisition by Abbott Laboratories (ABT 113 ***), in our view. The company did not provide 2026 guidance due to the pending merger and will not hold a Q4 analyst call. With the Abbott acquisition expected to close in Q2 2026, EXAS enters its final phase as a stand-alone public company with a strong balance sheet including $965M in cash and marketable securities, providing financial flexibility during the transition period.